Corcept Therapeutics Inc
CORT37.500USD
+0.970+2.66%
收盘 01/09, 16:00（美东）报价延迟15分钟
3.94B总市值
36.71市盈率 TTM
关于 Corcept Therapeutics Inc 公司
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
Corcept Therapeutics Inc简介
公司代码CORT
公司名称Corcept Therapeutics Inc
上市日期Apr 15, 2004
CEOBelanoff (Joseph K)
员工数量500
证券类型Ordinary Share
年结日Apr 15
公司地址101 Redwood Shores Parkway
城市REDWOOD CITY
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编94065
电话16506888803
网址https://www.corcept.com/
公司代码CORT
上市日期Apr 15, 2004
CEOBelanoff (Joseph K)
Corcept Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Joseph K. Belanoff, M.D.
Dr. Joseph K. Belanoff, M.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
2.98M
--
Mr. James N. (Jim) Wilson
Mr. James N. (Jim) Wilson
Independent Chairman of the Board
Independent Chairman of the Board
2.35M
+129142.00%
Mr. David L. Mahoney
Mr. David L. Mahoney
Independent Director
Independent Director
1.26M
--
Dr. Hazel Hunt, Ph.D.
Dr. Hazel Hunt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
183.41K
+64824.00%
Mr. Gary Charles (Charlie) Robb
Mr. Gary Charles (Charlie) Robb
Chief Business Officer, Secretary
Chief Business Officer, Secretary
101.05K
+65016.00%
Mr. Sean Maduck
Mr. Sean Maduck
President - Corcept Endocrinology
President - Corcept Endocrinology
97.87K
+275.00%
Mr. Atabak Mokari
Mr. Atabak Mokari
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
14.56K
+238.00%
Mr. Joseph Douglas Lyon
Mr. Joseph Douglas Lyon
Chief Accounting and Technology Officer
Chief Accounting and Technology Officer
10.52K
+246.00%
Mr. William Guyer, Pharm.D.
Mr. William Guyer, Pharm.D.
Chief Development Officer
Chief Development Officer
2.02K
-3265.00%
Mr. George Leonard Baker, Jr.
Mr. George Leonard Baker, Jr.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Joseph K. Belanoff, M.D.
Dr. Joseph K. Belanoff, M.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
2.98M
--
Mr. James N. (Jim) Wilson
Mr. James N. (Jim) Wilson
Independent Chairman of the Board
Independent Chairman of the Board
2.35M
+129142.00%
Mr. David L. Mahoney
Mr. David L. Mahoney
Independent Director
Independent Director
1.26M
--
Dr. Hazel Hunt, Ph.D.
Dr. Hazel Hunt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
183.41K
+64824.00%
Mr. Gary Charles (Charlie) Robb
Mr. Gary Charles (Charlie) Robb
Chief Business Officer, Secretary
Chief Business Officer, Secretary
101.05K
+65016.00%
Mr. Sean Maduck
Mr. Sean Maduck
President - Corcept Endocrinology
President - Corcept Endocrinology
97.87K
+275.00%
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
10.39%
The Vanguard Group, Inc.
9.05%
Ingalls & Snyder LLC (Asset Management)
7.32%
Renaissance Technologies LLC
5.79%
Baker (George Leonard Jr.)
5.05%
其他
62.41%
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
10.39%
The Vanguard Group, Inc.
9.05%
Ingalls & Snyder LLC (Asset Management)
7.32%
Renaissance Technologies LLC
5.79%
Baker (George Leonard Jr.)
5.05%
其他
62.41%
股东类型
持股股东
占比
Investment Advisor
41.70%
Investment Advisor/Hedge Fund
22.82%
Individual Investor
11.70%
Hedge Fund
7.39%
Pension Fund
1.39%
Sovereign Wealth Fund
0.96%
Research Firm
0.74%
Bank and Trust
0.43%
Family Office
0.06%
其他
12.82%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
801
79.27M
75.36%
-8.80M
2025Q3
810
79.55M
83.49%
-543.84K
2025Q2
778
80.03M
86.89%
-4.55M
2025Q1
736
84.99M
89.94%
-9.90M
2024Q4
668
86.02M
93.22%
-3.95M
2024Q3
614
90.10M
96.25%
-1.26M
2024Q2
578
91.29M
99.95%
-4.43M
2024Q1
572
95.57M
89.61%
+2.81M
2023Q4
546
86.50M
88.14%
+1.82M
2023Q3
531
84.62M
88.02%
+2.14M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BlackRock Institutional Trust Company, N.A.
10.93M
10.39%
-380.74K
-3.37%
Sep 30, 2025
The Vanguard Group, Inc.
9.51M
9.05%
-144.25K
-1.49%
Sep 30, 2025
Ingalls & Snyder LLC (Asset Management)
7.70M
7.32%
-24.94K
-0.32%
Sep 30, 2025
Renaissance Technologies LLC
6.09M
5.79%
-177.06K
-2.83%
Sep 30, 2025
Baker (George Leonard Jr.)
5.31M
5.05%
--
--
Apr 17, 2025
Parallel Advisors, LLC
3.87M
3.68%
+329.00
+0.01%
Sep 30, 2025
Belanoff (Joseph K)
2.98M
2.83%
--
--
Dec 24, 2025
State Street Investment Management (US)
2.97M
2.82%
+2.81K
+0.09%
Sep 30, 2025
Wilson (James N)
2.35M
2.23%
+129.14K
+5.82%
Apr 17, 2025
Fidelity Management & Research Company LLC
2.15M
2.04%
+789.13K
+58.16%
Sep 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Invesco S&P SmallCap Health Care ETF
4.22%
First Trust NYSE Arca Biotechnology Index Fund
3.34%
Invesco Pharmaceuticals ETF
2.82%
State Street SPDR S&P Pharmaceuticals ETF
2.67%
iShares U.S. Pharmaceuticals ETF
2.55%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.48%
Formidable ETF
2.47%
Alger Russell Innovation ETF
2.09%
Invesco S&P SmallCap 600 Pure Growth ETF
1.73%
Fidelity Stocks for Inflation ETF
1.52%
查看更多
Invesco S&P SmallCap Health Care ETF
占比4.22%
First Trust NYSE Arca Biotechnology Index Fund
占比3.34%
Invesco Pharmaceuticals ETF
占比2.82%
State Street SPDR S&P Pharmaceuticals ETF
占比2.67%
iShares U.S. Pharmaceuticals ETF
占比2.55%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
占比2.48%
Formidable ETF
占比2.47%
Alger Russell Innovation ETF
占比2.09%
Invesco S&P SmallCap 600 Pure Growth ETF
占比1.73%
Fidelity Stocks for Inflation ETF
占比1.52%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Corcept Therapeutics Inc的前五大股东是谁？
Corcept Therapeutics Inc 的前五大股东如下：
BlackRock Institutional Trust Company, N.A.持有股份：10.93M，占总股份比例：10.39%。
The Vanguard Group, Inc.持有股份：9.51M，占总股份比例：9.05%。
Ingalls & Snyder LLC (Asset Management)持有股份：7.70M，占总股份比例：7.32%。
Renaissance Technologies LLC持有股份：6.09M，占总股份比例：5.79%。
Baker (George Leonard Jr.)持有股份：5.31M，占总股份比例：5.05%。
BlackRock Institutional Trust Company, N.A.持有股份：10.93M，占总股份比例：10.39%。
The Vanguard Group, Inc.持有股份：9.51M，占总股份比例：9.05%。
Ingalls & Snyder LLC (Asset Management)持有股份：7.70M，占总股份比例：7.32%。
Renaissance Technologies LLC持有股份：6.09M，占总股份比例：5.79%。
Baker (George Leonard Jr.)持有股份：5.31M，占总股份比例：5.05%。
Corcept Therapeutics Inc的前三大股东类型是什么？
Corcept Therapeutics Inc 的前三大股东类型分别是：
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Ingalls & Snyder LLC (Asset Management)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Ingalls & Snyder LLC (Asset Management)
有多少机构持有Corcept Therapeutics Inc(CORT)的股份？
截至2025Q4，共有801家机构持有Corcept Therapeutics Inc的股份，合计持有的股份价值约为79.27M，占公司总股份的75.36%。与2025Q3相比，机构持股有所增加，增幅为-8.13%。
哪个业务部门对Corcept Therapeutics Inc的收入贡献最大？
在--，--业务部门对Corcept Therapeutics Inc的收入贡献最大，创收--，占总收入的--%。
